Corrilynn O Hileman1, Randi Turner, Nicholas T Funderburg, Richard D Semba, Grace A McComsey. 1. aMetroHealth Medical CenterbCase Western Reserve University School of Medicine, Cleveland, OhiocWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylanddOhio State University School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, ColumbuseUniversity Hospitals Case Medical Center, Cleveland, Ohio, USA.
Abstract
BACKGROUND:Oxidative stress plays a significant role in atherosclerosis development. HIV infection has been linked with heightened cardiovascular disease risk. HMG-CoA reductase inhibitors may reduce oxidative stress and subsequently subclinical vascular disease in HIV. DESIGN/ METHODS: This is a randomized, placebo-controlled trial to evaluate the effect of rosuvastatin in HIV-infected adults on stable antiretroviral therapy with low-density lipoprotein less than 130 mg/dl and increased inflammation or T-cell activation on subclinical vascular disease. Changes over 48 weeks in oxidative stress markers, oxidized low-density lipoprotein (oxLDL) and F2-isoprostane/creatinine ratio (F2-IsoP/Cr), were compared between groups. Spearman correlation and multivariable linear regression were used to evaluate relationships between changes in markers of oxidative stress, inflammation and monocyte activation and carotid intima media thickness (CIMT). RESULTS:One hundred and forty-seven adults enrolled (72 torosuvastatin and 75 to placebo). In the rosuvastatin group, oxLDL decreased significantly over 24 weeks compared to placebo [mean absolute change in log-oxLDL for rosuvastatin -0.2 ± 0.468 log U/l (P < 0.001 within-group) vs. placebo -0.018 ± 0.456 log U/l (P = 0.83 within-group); P = 0.004 between groups] and this change was linked with changes in soluble CD14 and proportion of patrolling monocytes (CD14dimCD16). Although oxLDL levels increased after initially declining and were not different from placebo at week 48, the early improvement in oxLDL was associated with improved CIMT at week 48. Changes in F2-IsoP/Cr were not significant between groups. CONCLUSION:Rosuvastatin decreases oxLDL levels early after initiation and is associated with decreased monocyte activation. Early improvement in oxLDL is linked with improved CIMT in treated HIV infection.
RCT Entities:
BACKGROUND: Oxidative stress plays a significant role in atherosclerosis development. HIV infection has been linked with heightened cardiovascular disease risk. HMG-CoA reductase inhibitors may reduce oxidative stress and subsequently subclinical vascular disease in HIV. DESIGN/ METHODS: This is a randomized, placebo-controlled trial to evaluate the effect of rosuvastatin in HIV-infected adults on stable antiretroviral therapy with low-density lipoprotein less than 130 mg/dl and increased inflammation or T-cell activation on subclinical vascular disease. Changes over 48 weeks in oxidative stress markers, oxidized low-density lipoprotein (oxLDL) and F2-isoprostane/creatinine ratio (F2-IsoP/Cr), were compared between groups. Spearman correlation and multivariable linear regression were used to evaluate relationships between changes in markers of oxidative stress, inflammation and monocyte activation and carotid intima media thickness (CIMT). RESULTS: One hundred and forty-seven adults enrolled (72 to rosuvastatin and 75 to placebo). In the rosuvastatin group, oxLDL decreased significantly over 24 weeks compared to placebo [mean absolute change in log-oxLDL for rosuvastatin -0.2 ± 0.468 log U/l (P < 0.001 within-group) vs. placebo -0.018 ± 0.456 log U/l (P = 0.83 within-group); P = 0.004 between groups] and this change was linked with changes in soluble CD14 and proportion of patrolling monocytes (CD14dimCD16). Although oxLDL levels increased after initially declining and were not different from placebo at week 48, the early improvement in oxLDL was associated with improved CIMT at week 48. Changes in F2-IsoP/Cr were not significant between groups. CONCLUSION:Rosuvastatin decreases oxLDL levels early after initiation and is associated with decreased monocyte activation. Early improvement in oxLDL is linked with improved CIMT in treated HIV infection.
Authors: Dimitrios Tsikas; Vu Vi Pham; Maria-Theresia Suchy; Marcel A van de Ree; Menno V Huisman; Jürgen C Frölich; Hans M G Princen Journal: Pharmacol Res Date: 2015-02-07 Impact factor: 7.658
Authors: Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Norma Storer; Danielle Labbato; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey Journal: Clin Infect Dis Date: 2013-11-18 Impact factor: 9.079
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Bonnie Ky; Anne Burke; Sotirios Tsimikas; Megan L Wolfe; Mahlet G Tadesse; Philippe O Szapary; Joseph L Witztum; Garret A FitzGerald; Daniel J Rader Journal: J Am Coll Cardiol Date: 2008-04-29 Impact factor: 24.094
Authors: Nicholas T Funderburg; Dihua Xu; Martin P Playford; Aditya A Joshi; Adriana Andrade; Daniel R Kuritzkes; Michael M Lederman; Nehal N Mehta Journal: Antivir Ther Date: 2016-10-14
Authors: Theodoros Kelesidis; Nicholas Jackson; Grace A McComsey; Xiaoyan Wang; David Elashoff; Michael P Dube; Todd T Brown; Otto O Yang; James H Stein; Judith S Currier Journal: AIDS Date: 2016-11-13 Impact factor: 4.177